Cervimycin A-D: a polyketide glycoside complex from a cave bacterium can defeat vancomycin resistance.

Cervimycins A-D are novel polyketide glycosides with significant activity against multi-drug-resistant staphylococci and vancomycin-resistant enterococci. They are produced by a strain of Streptomyces tendae, isolated from an ancient cave. The structures of the cervimycins were determined by performing extensive NMR and chemical degradation studies. All cervimycins have a common tetracyclic polyketide core that is substituted with unusual di- and tetrasaccharide chains, composed exclusively of trideoxysugars; however, they differ in the acetyl and carbamoyl ring substituent and in the highly unusual terminal methylmalonyl and dimethylmalonyl residues.

Biosynthesis of cervimycin C, an aromatic polyketide antibiotic bearing an unusual dimethylmalonyl moiety.

Cervimycin C is the major component of an antibiotic complex produced by Streptomyces tendae HKI-179 consisting of a tetracycline-type aglycon, six tridesoxysugars and a rare dimethylmalonyl moiety. The biosynthetic origin of cervimycin was studied by molecular studies and feeding experiments, which reveal that the dimethylmalonate unit is not derived from malonate, but from valine.